 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- live-attenuated Bordetella pertussis vaccine (BPZE1) / ILiAD Biotechnologies
Immunogenicity and Safety of BPZE1, an Intranasal Live Attenuated Pertussis Vaccine, Evaluated With and Without Tdap in Healthy Children 6 to 17 Years Old: A Phase 2b, Randomized, Active-Controlled Study (403 B) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_978;
- ||| live-attenuated Bordetella pertussis vaccine (BPZE1) / ILiAD Biotechnologies
Trial completion, Phase classification: CHAMPION-1: Pertussis Challenge Study in Adults Vaccinated With BPZE1 (clinicaltrials.gov) - Feb 22, 2024
P2, N=53, Completed, Sponsor: ILiAD Biotechnologies
Active, not recruiting --> Completed | Phase classification: P2b --> P2
- ||| live-attenuated Bordetella pertussis vaccine (BPZE1) / ILiAD Biotechnologies
Enrollment closed, Phase classification, Enrollment change: Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children (clinicaltrials.gov) - Dec 1, 2023
P2, N=360, Active, not recruiting, Sponsor: ILiAD Biotechnologies
Active, not recruiting --> Completed | Phase classification: P2b --> P2 Recruiting --> Active, not recruiting | Phase classification: P2b --> P2 | N=600 --> 360
- live-attenuated Bordetella pertussis vaccine (BPZE1) / ILiAD Biotechnologies
BPZE1, an intranasal live attenuated pertussis vaccine, evaluated in a bordetella pertussis challenge study in healthy adults: a phase 2b, randomized, placebo-controlled study (Room 5) - Oct 20, 2023 - Abstract #WVCE2023WVCE_225;
- || live-attenuated Bordetella pertussis vaccine (BPZE1) / ILiAD Biotechnologies
Enrollment closed: CHAMPION-1: Pertussis Challenge Study in Adults Vaccinated With BPZE1 (clinicaltrials.gov) - Aug 4, 2023
P2b, N=53, Active, not recruiting, Sponsor: ILiAD Biotechnologies
Recruiting --> Active, not recruiting | Phase classification: P2b --> P2 | N=600 --> 360 Recruiting --> Active, not recruiting
- || live-attenuated Bordetella pertussis vaccine (BPZE1) / ILiAD Biotechnologies
Enrollment open: CHAMPION-1: Pertussis Challenge Study in Adults Vaccinated With BPZE1 (clinicaltrials.gov) - May 9, 2023
P2b, N=44, Recruiting, Sponsor: ILiAD Biotechnologies
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- || live-attenuated Bordetella pertussis vaccine (BPZE1) / ILiAD Biotechnologies
Trial completion date, Trial primary completion date: Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children (clinicaltrials.gov) - May 3, 2023
P2b, N=600, Recruiting, Sponsor: ILiAD Biotechnologies
Active, not recruiting --> Recruiting Trial completion date: Jan 2024 --> Apr 2024 | Trial primary completion date: Jan 2024 --> Apr 2024
- | live-attenuated Bordetella pertussis vaccine (BPZE1) / ILiAD Biotechnologies
Enrollment closed: CHAMPION-1: Pertussis Challenge Study in Adults Vaccinated With BPZE1 (clinicaltrials.gov) - May 3, 2023
P2b, N=44, Active, not recruiting, Sponsor: ILiAD Biotechnologies
Trial completion date: Jan 2024 --> Apr 2024 | Trial primary completion date: Jan 2024 --> Apr 2024 Recruiting --> Active, not recruiting
- || live-attenuated Bordetella pertussis vaccine (BPZE1) / ILiAD Biotechnologies
P2b data, Journal: Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus-diphtheria-acellular pertussis vaccine: a randomised, double-blind, phase 2b trial. (Pubmed Central) - Mar 16, 2023
P2b
BPZE1 has the potential to avert B pertussis infections, which ultimately could lead to reduced transmission and diminished epidemic cycles. These results should be confirmed in large phase 3 trials.
- | live-attenuated Bordetella pertussis vaccine (BPZE1) / ILiAD Biotechnologies
Trial completion date, Trial primary completion date: CHAMPION-1: Pertussis Challenge Study in Adults Vaccinated With BPZE1 (clinicaltrials.gov) - Mar 9, 2023
P2b, N=44, Recruiting, Sponsor: ILiAD Biotechnologies
These results should be confirmed in large phase 3 trials. Trial completion date: Jun 2023 --> Sep 2023 | Trial primary completion date: Mar 2023 --> Jul 2023
- || live-attenuated Bordetella pertussis vaccine (BPZE1) / ILiAD Biotechnologies
Trial completion date, Trial primary completion date: Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children (clinicaltrials.gov) - Mar 1, 2023
P2b, N=600, Recruiting, Sponsor: ILiAD Biotechnologies
Trial completion date: Jun 2023 --> Sep 2023 | Trial primary completion date: Mar 2023 --> Jul 2023 Trial completion date: Dec 2022 --> Jan 2024 | Trial primary completion date: Dec 2022 --> Jan 2024
- | live-attenuated Bordetella pertussis vaccine (BPZE1) / ILiAD Biotechnologies
Journal: Safety and immunogenicity of live, attenuated intranasal Bordetella pertussis vaccine (BPZE1) in healthy adults. (Pubmed Central) - Nov 8, 2022
Lyophilized BPZE1 vaccine was well tolerated and immunogenic at the highest dose (10 CFU) delivered intranasally by VaxINator device and was not associated with any SAEs or prolonged shedding of BPZE1. Further evaluation of BPZE1 is warranted.
- ||||| live-attenuated Bordetella pertussis vaccine (BPZE1) / ILiAD Biotechnologies
Clinical: ILiAD Biotechnologies Announces $42.8M Financing Round to Advance BPZE1 Pertussis Vaccine https://t.co/KlIRB7lZ4N (Twitter) - Sep 6, 2022
- ||| live-attenuated Bordetella pertussis vaccine (BPZE1) / ILiAD Biotechnologies
New P2b trial: CHAMPION-1: Pertussis Challenge Study in Adults Vaccinated With BPZE1 (clinicaltrials.gov) - Jul 15, 2022
P2b, N=44, Recruiting, Sponsor: ILiAD Biotechnologies
- |||| live-attenuated Bordetella pertussis vaccine (BPZE1) / ILiAD Biotechnologies
Enrollment open: Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children (clinicaltrials.gov) - Jan 19, 2022
P2b, N=600, Recruiting, Sponsor: ILiAD Biotechnologies
Further evaluation of BPZE1 is warranted. Not yet recruiting --> Recruiting
- |||||| live-attenuated Bordetella pertussis vaccine (BPZE1) / ILiAD Biotechnologies
New P2b trial: Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children (clinicaltrials.gov) - Nov 9, 2021
P2b, N=600, Not yet recruiting, Sponsor: ILiAD Biotechnologies
- live-attenuated Bordetella pertussis vaccine (BPZE1) / ILiAD Biotechnologies, Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine) / GSK
[VIRTUAL] Serum Bactericidal Activity Induced by Live Attenuated Pertussis Vaccine BPZE1 is Comparable to Boostrix™ () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_2040;
SBA-Prn correlations were high post-Boostrix, consistent with prior reports showing Prn is the acellular vaccine antigen that mediates SBA. In contrast, BPZE1 bactericidal antibodies appear broader than Prn which may be important given the global rise of Prn-deficient B. pertussis strains.
- |||| live-attenuated Bordetella pertussis vaccine (BPZE1) / ILiAD Biotechnologies
Trial completion, Trial completion date: Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults (clinicaltrials.gov) - Jul 9, 2020
P2b, N=300, Completed, Sponsor: ILiAD Biotechnologies
In contrast, BPZE1 bactericidal antibodies appear broader than Prn which may be important given the global rise of Prn-deficient B. pertussis strains. Enrolling by invitation --> Completed | Trial completion date: Oct 2020 --> Jun 2020
- | live-attenuated Bordetella pertussis vaccine (BPZE1) / ILiAD Biotechnologies
Enrollment open, Phase classification: Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults (clinicaltrials.gov) - Sep 15, 2019
P2b, N=300, Enrolling by invitation, Sponsor: ILiAD Biotechnologies
Enrolling by invitation --> Completed | Trial completion date: Oct 2020 --> Jun 2020 Withheld --> Enrolling by invitation | Phase classification: PN/A --> P2b
- | live-attenuated Bordetella pertussis vaccine (BPZE1) / ILiAD Biotechnologies
New P2b trial, New trial: Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults (clinicaltrials.gov) - May 7, 2019
P, N=0, Withheld, Sponsor: [Redacted]